Literature DB >> 8862139

Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis.

F Nicoletti1, F Patti, C Cocuzza, P Zaccone, A Nicoletti, R Di Marco, A Reggio.   

Abstract

The serum levels of the heterodimeric cytokine IL-12 were measured by solid-phase ELISA in a group of healthy subjects, multiple sclerosis (MS) patients with secondary chronic progressive course of the disease and patients suffering from other neurological diseases (OND). Serum levels of IL-12 higher than 5 pg/ml (limit of sensitivity of the assay) were only found in 2/30 (6.7%) of the healthy subjects and none of the 8 subjects with OND. In contrast, IL-12 was found in the majority of CPMS patients' sera (10/15, 66.7%) with values ranging between 5.5 and 18.6 pg/ml. These results are suggestive for an up-regulated production of IL-12 in CPMS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862139     DOI: 10.1016/s0165-5728(96)00101-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  24 in total

1.  Monocyte-derived cytokines in multiple sclerosis.

Authors:  L G Filion; G Graziani-Bowering; D Matusevicius; M S Freedman
Journal:  Clin Exp Immunol       Date:  2003-02       Impact factor: 4.330

Review 2.  Mechanisms regulating regional localization of inflammation during CNS autoimmunity.

Authors:  Emily Pierson; Sarah B Simmons; Luca Castelli; Joan M Goverman
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 3.  Immunotherapy of inflammatory demyelinating diseases of the central nervous system.

Authors:  J J Bright; S Sriram
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 4.  Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.

Authors:  Bharath Wootla; Jens O Watzlawik; Nikolaos Stavropoulos; Nathan J Wittenberg; Harika Dasari; Murtada A Abdelrahim; John R Henley; Sang-Hyun Oh; Arthur E Warrington; Moses Rodriguez
Journal:  Expert Opin Biol Ther       Date:  2016-03-10       Impact factor: 4.388

5.  COX-2 inhibitors modulate IL-12 signaling through JAK-STAT pathway leading to Th1 response in experimental allergic encephalomyelitis.

Authors:  Gladson Muthian; Himanshu P Raikwar; Caroline Johnson; Johnson Rajasingh; Amit Kalgutkar; Lawrence J Marnett; John J Bright
Journal:  J Clin Immunol       Date:  2006-01       Impact factor: 8.317

6.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

7.  The attenuating effects of plumbagin on pro-inflammatory cytokine expression in LPS-activated BV-2 microglial cells.

Authors:  Samia S Messeha; Najla O Zarmouh; Patricia Mendonca; Malak G Kolta; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2017-09-20       Impact factor: 3.478

8.  Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.

Authors:  M Comabella; K Balashov; S Issazadeh; D Smith; H L Weiner; S J Khoury
Journal:  J Clin Invest       Date:  1998-08-15       Impact factor: 14.808

Review 9.  APC-derived cytokines and T cell polarization in autoimmune inflammation.

Authors:  Ilona Gutcher; Burkhard Becher
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients.

Authors:  B M Brooks-Worrell; J P Palmer
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.